RS53635B1 - Tikagrelor za tretman aneurizama abdominalne aorte - Google Patents

Tikagrelor za tretman aneurizama abdominalne aorte

Info

Publication number
RS53635B1
RS53635B1 RS20140600A RSP20140600A RS53635B1 RS 53635 B1 RS53635 B1 RS 53635B1 RS 20140600 A RS20140600 A RS 20140600A RS P20140600 A RSP20140600 A RS P20140600A RS 53635 B1 RS53635 B1 RS 53635B1
Authority
RS
Serbia
Prior art keywords
compound
treatment
thrombus
rats
days
Prior art date
Application number
RS20140600A
Other languages
English (en)
Serbian (sr)
Inventor
Jean-Baptiste Michel
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of RS53635B1 publication Critical patent/RS53635B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20140600A 2007-12-03 2008-12-02 Tikagrelor za tretman aneurizama abdominalne aorte RS53635B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07301616 2007-12-03
PCT/SE2008/051386 WO2009072967A1 (en) 2007-12-03 2008-12-02 Triazolo [4,5-d] pyrimidine compounds for treatment of abdominal aortic aneurysms

Publications (1)

Publication Number Publication Date
RS53635B1 true RS53635B1 (sr) 2015-04-30

Family

ID=40717966

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20140600A RS53635B1 (sr) 2007-12-03 2008-12-02 Tikagrelor za tretman aneurizama abdominalne aorte

Country Status (24)

Country Link
US (2) US20100298350A1 (https=)
EP (1) EP2229172B1 (https=)
JP (1) JP5701060B2 (https=)
KR (1) KR101563757B1 (https=)
CN (2) CN103919781A (https=)
AU (1) AU2008331984B2 (https=)
BR (1) BRPI0819458A2 (https=)
CA (1) CA2707488C (https=)
CY (1) CY1115760T1 (https=)
DK (1) DK2229172T3 (https=)
EA (1) EA201000928A1 (https=)
ES (1) ES2522317T3 (https=)
HR (1) HRP20141081T1 (https=)
IL (1) IL205613A (https=)
MX (1) MX2010006101A (https=)
MY (1) MY159656A (https=)
NZ (1) NZ585513A (https=)
PL (1) PL2229172T3 (https=)
PT (1) PT2229172E (https=)
RS (1) RS53635B1 (https=)
SI (1) SI2229172T1 (https=)
UA (1) UA100864C2 (https=)
WO (1) WO2009072967A1 (https=)
ZA (1) ZA201003599B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
WO2013033178A1 (en) 2011-08-30 2013-03-07 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199800019T1 (xx) * 1995-07-11 1998-05-21 Astra Pharmaceuticals Limited Trombosit topaklanmas�n� �nleyici yeni maddeler.
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
WO2009007675A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist

Also Published As

Publication number Publication date
KR101563757B1 (ko) 2015-10-27
EP2229172A4 (en) 2012-12-26
IL205613A0 (en) 2010-11-30
MX2010006101A (es) 2010-10-04
BRPI0819458A2 (pt) 2015-05-05
JP5701060B2 (ja) 2015-04-15
NZ585513A (en) 2012-07-27
EA201000928A1 (ru) 2010-12-30
ES2522317T3 (es) 2014-11-14
CY1115760T1 (el) 2017-01-25
CN101883565A (zh) 2010-11-10
CA2707488A1 (en) 2009-06-11
PT2229172E (pt) 2014-11-03
US20100298350A1 (en) 2010-11-25
DK2229172T3 (da) 2014-11-10
EP2229172A1 (en) 2010-09-22
JP2011505417A (ja) 2011-02-24
CN103919781A (zh) 2014-07-16
HK1148195A1 (en) 2011-09-02
AU2008331984B2 (en) 2012-08-16
US20150272955A1 (en) 2015-10-01
SI2229172T1 (sl) 2014-12-31
AU2008331984A1 (en) 2009-06-11
PL2229172T3 (pl) 2015-01-30
MY159656A (en) 2017-01-13
IL205613A (en) 2015-04-30
HRP20141081T1 (hr) 2015-01-02
WO2009072967A1 (en) 2009-06-11
EP2229172B1 (en) 2014-09-10
ZA201003599B (en) 2012-10-31
KR20100099175A (ko) 2010-09-10
UA100864C2 (uk) 2013-02-11
CA2707488C (en) 2015-07-28

Similar Documents

Publication Publication Date Title
Roach et al. Ca2+ signalling in fibroblasts and the therapeutic potential of KCa3. 1 channel blockers in fibrotic diseases
Duffield et al. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis
US20200206169A1 (en) Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
CA2998509A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
US20120046333A1 (en) Methods and Compositions of PI-3 Kinase Inhibitors for Treating Fibrosis
RS53635B1 (sr) Tikagrelor za tretman aneurizama abdominalne aorte
AU2003210447A1 (en) Nitric oxide donors for treatment of disease and injury
CN109152767B (zh) 用血栓烷-a2受体拮抗剂治疗肌营养不良的组合物和方法
US12115287B2 (en) Methods and materials for reducing venous neointimal hyperplasia of an arteriovenous fistula or graft
EP1807086A1 (en) Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
Uil et al. Platelet inhibition by ticagrelor is protective against diabetic nephropathy in mice
MXPA06013157A (es) Uso de dipiridamol para el tratamiento de la resistencia a los inhibidores de plaquetas.
US20150258127A1 (en) Methods for preventing antiphospholipid syndrome (aps)
HK1148195B (en) Ticagrelor for treatment of abdominal aortic aneurysms
AU2002329872B2 (en) Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
TWI344366B (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
Ribatti et al. An experimental study in the chick embryo chorioallantoic membrane of the anti-angiogenic activity of cyclosporine in rheumatoid arthritis versus osteoarthritis
Noji et al. Treatment with an adenosine uptake inhibitor attenuates glomerulonephritis in mice
Jin et al. Roles of chymase in stenosis occurring after polytetrafluoroethylene graft implantations
Smith et al. Type II collagen-induced arthritis in the diabetic-resistant biobreeding rat: inflammatory and histopathological features of joint pathology and effects of antiinflammatory and antirheumatic drugs on this chronic arthritic process.
US20260060965A1 (en) Modulating the acute foreign body reaction to reduce stenosis
HK1258734B (en) Compositions and methods of treating muscular dystrophy with thromboxane-a2 receptor antagonists